A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes



Status:Recruiting
Conditions:Blood Cancer, Blood Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - Any
Updated:7/15/2018
Start Date:November 14, 2016
End Date:June 21, 2021
Contact:Associate Director Clinical Trial Disclosure
Email:clinicaltrialdisclosure@celgene.com
Phone:1-888-260-1599

Use our guide to learn which trials are right for you!

A Phase 1, Open-label, Dose-Finding Study of CC-90009, a Novel Cereblon E3 Ligase Modulating Drug, in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects
with relapsed or refractory acute myeloid leukemia and relapsed or refractory high-risk
myelodysplastic syndrome.

Study CC-90009-AML-001 is an open-label, Phase 1, dose escalation and expansion,
first-in-human clinical study of CC-90009 in subjects with relapsed or refractory acute
myeloid leukemia (AML) and relapsed or refractory high-risk myelodysplastic syndrome.

The dose escalation part (Part A) of the study will evaluate the safety and tolerability of
escalating doses of CC-90009 in relapsed and refractory AML. The expansion part, (Part B),
will further evaluate the safety and efficacy of CC-90009 administered at or below the
maximum tolerated dose (MTD) in selected expansion cohorts of one or more dosing regimens in
order to determine the recommended Phase 2 dose (RP2D) for subjects with relapsed or
refractory AML and relapsed or refractory high-risk myelodysplastic syndrome.

Inclusion Criteria:

1. Men and women ≥ 18 years of age, at the time of signing the ICD (Informed Consent
Document).

2. Subject must understand and voluntarily sign an ICD prior to any study-related
assessments/procedures being conducted.

3. Relapsed or refractory AML (Acute Myeloid Leukemia) (Parts A and B) or relapsed or
refractory high-risk MDS (Myelodysplastic Syndrome) (Part B only) as defined by World
Health Organization criteria who are not suitable for other established therapies.

4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2.

5. At least 4 weeks (from first dose) has elapsed from donor lymphocyte infusion (DLI)
without conditioning.

6. Subjects must have the following screening laboratory values:

- Total White Blood Cell count (WBC) < 25 x 109/L prior to first infusion. Prior or
concurrent treatment with hydroxyurea to achieve this level is allowed.

- Selected electrolytes within normal limits or correctable with supplements.

- Serum bilirubin ≤ 1.5 x ULN (upper limit of normal).

- Estimated serum creatinine clearance of ≥ 60 mL/min using the Cockcroft-Gault
equation.

7. Agree to follow the CC-90009 Pregnancy Prevention Plan (PPP)

Exclusion Criteria:

1. Subjects with acute promyelocytic leukemia (APL)

2. Subjects with clinical symptoms suggesting active central nervous system (CNS)
leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid is only required if
there is clinical suspicion of CNS involvement by leukemia during screening.

3. Patients with prior autologous hematopoietic stem cell transplant who, in the
investigator's judgment, have not fully recovered from the effects of the last
transplant (e.g., transplant related side effects).

4. Prior allogeneic hematopoietic stem cell transplant (HSCT) with either standard or
reduced intensity conditioning ≤ 6 months prior to starting CC-90009.

5. Subjects on systemic immunosuppressive therapy post HSCT at the time of screening, or
with clinically significant graft-versus-host disease (GVHD). The use of topical
steroids for ongoing skin or ocular GVHD is permitted.

6. Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half lives
or 4 weeks prior to starting CC-90009, whichever is shorter. Hydroxyurea is allowed to
control peripheral leukemia blasts.

7. Leukapheresis ≤ 2 weeks prior to starting CC-90009.
We found this trial at
8
sites
30 Prospect Ave
Hackensack, New Jersey 07601
(201) 996-2000
Hackensack University Medical Center Hackensack University Medical Center, part of the Hackensack University Health Network,...
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Chicago, Illinois 60601
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Duarte, California 91010
?
mi
from
Duarte, CA
Click here to add this to my saved trials
333 Cedar Street
New Haven, Connecticut 06520
(203) 785-4095
Yale Cancer Center Yale Cancer Center combines a tradition of innovative cancer treatment and quality...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
4960 Childrens Place
Saint Louis, Missouri 63110
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
?
mi
from
Toronto,
Click here to add this to my saved trials